A Study to Evaluate Bevacizumab Alone or in Combination With Irinotecan for Treatment of Glioblastoma Multiforme (BRAIN)
This is a Phase II, open-label, multicenter, randomized, non comparative study consisting of two concurrent single-arms. Approximately 160 subjects will be randomized in a 1:1 ratio to Arm 1 (bevacizumab alone) or Arm 2 (bevacizumab + irinotecan).
Glioblastoma
DRUG: bevacizumab|DRUG: irinotecan
Objective response, as determined by the independent review facility (IRF), Complete response or partial response, determined on two consecutive assessments ≥4 weeks apart|Progression-free survival, as determined by the IRF, 6 months
Incidence of adverse events and serious adverse events, Length of patient on study|Duration of objective response, as determined by the IRF, Complete or partial response determined on two consecutive assessments ≥4 weeks apart|Overall survival, Time from randomization to death
This is a Phase II, open-label, multicenter, randomized, non comparative study consisting of two concurrent single-arms. Approximately 160 subjects will be randomized in a 1:1 ratio to Arm 1 (bevacizumab alone) or Arm 2 (bevacizumab + irinotecan).